Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Richard Greil, Sonja Burgstaller et al.|Blood|2015Cited by 186
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2bNicole C.C. Them, Róbert Královics, Klaudia Bagienski et al.|American Journal of Hematology|2014Cited by 54
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasmsC. Pecquet, Stefan N. Constantinescu, Nicolas Papadopoulos et al.|Blood|2022Cited by 46
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera StudVeronika Buxhofer‐Ausch, Richard Greil, Heinz Gisslinger et al.|Blood|2015Cited by 1
Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera PatientHeinz Gisslinger, Richard Greil, Veronika Buxhofer‐Ausch et al.|Blood|2015Cited by 0